Nektar Therapeutics Finalizes Terms for $150M At-The-Market Offering
NKTR has more than doubled off its 52-week low of $7.99.
Summary
Nektar Therapeutics filed a prospectus supplement to finalize the terms of its previously announced At-The-Market (ATM) equity offering, allowing it to sell up to $150 million in common stock.
Key Events · Financing and Capital Events · NKTR
-
Finalizes $150 Million At-The-Market Offering
Nektar Therapeutics has filed a prospectus supplement to establish an At-The-Market (ATM) equity offering program, enabling the company to sell up to $150,000,000 of its common stock from time to time through sales agents Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC. This filing operationalizes the program announced in a concurrent 8-K filing.
-
Capital for R&D and Clinical Development
The net proceeds from this offering are intended for general corporate purposes, including funding research and development, clinical development costs (specifically mentioning Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing to advance its drug candidates.
-
Potential Share Dilution
The offering, if fully utilized, could result in the issuance of approximately 1,762,839 shares based on a recent market price, representing potential dilution to existing shareholders. The filing notes an immediate dilution of $54.51 per share to new investors at an assumed offering price of $85.09 per share.
Analysis · NKTR · Life Sciences
This 424B5 prospectus supplement provides the full legal framework and detailed terms for the At-The-Market (ATM) equity offering program, which was initially announced via an 8-K filing on May 8, 2026. The offering allows Nektar to sell up to $150 million of common stock from time to time through sales agents. While dilutive, this program is crucial for a clinical-stage biopharmaceutical company like Nektar to secure capital for general corporate purposes, including funding ongoing research and development, clinical trials (such as Phase 3 trials for rezpegaldesleukin), and manufacturing costs. The ability to access capital is vital for extending the company's operational runway, especially following its recent Q1 earnings report which showed a narrowed net loss and increased cash reserves. Investors should monitor the pace and pricing of future sales under this program.
At the time of this filing, NKTR was trading at $82.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $7.99 to $109.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.